Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Nanotechnology Drug Delivery Market size was over USD 97 billion in 2024 and is estimated to reach USD 362 billion by the end of 2037, expanding at a CAGR of 11.6% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of nanotechnology drug delivery is assessed at USD 108.3 billion.
The rising incidence of cancer, cardiovascular diseases, and neurological disorders is fueling the demand for advanced drug delivery systems that improve treatment outcomes. According to estimates from NLM, the number of cancer cases will rise by 12.8% in 2025 compared to 2020. Traditional therapies often have limitations, such as poor bioavailability and severe side effects. Nanotechnology enables precise drug targeting, enhancing therapeutic efficacy while minimizing toxicity. By improving drug solubility and controlled release, nanotechnology-based drug delivery systems offer more effective treatments, particularly in oncology and chronic disease management, driving market growth.
Additionally, innovations in liposomes, polymeric nanoparticles, and lipid-based carriers are revolutionizing drug delivery by enhancing drug stability and controlled release. These advanced nanocarriers protect therapeutic compounds from degradation, ensuring prolonged circulation and targeted delivery to diseased tissues. Improving bioavailability and reducing toxicity enable more effective treatments for cancer, infectious diseases, and neurological disorders. This progress in the nanotechnology drug delivery market is driving the development of safer, more efficient, and personalized medical therapies.
Nanotechnology Drug Delivery Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing adoption of lipid nanoparticles for mRNA therapies: The success of mRNA-based COVID-19 vaccines has highlighted the potential of lipid nanoparticles (LNPs) as highly efficient drug carriers, accelerating their adoption in various therapeutic areas. LNPs enhance mRNA stability, protect it from degradation, and enable targeted delivery, making them ideal for vaccines, gene therapies, and cancer treatments. This breakthrough has increased R&D investments and regulatory approvals, expanding the nanotechnology drug delivery market and driving innovation in precision medicine and next-generation therapeutics.
- Improvement in drug kinetics and administration: Nanotechnology enhances drug absorption and targeted delivery by enabling precise localization of therapeutic agents at disease sites, reducing systemic toxicity and side effects. In Saudi Arabia, it was discovered that formulations based on nanotechnology had an overall improvement power of 7.9% (2022 ScienceDirect study). This encompasses additional benefits over conventional therapies. In addition, improved drug bioavailability and efficacy make nanotechnology-based delivery systems a suitable option for higher treatment success. Thus, the growing demand for safer, more effective therapies is driving R&D investments and expanding the nanotechnology drug delivery market globally.
Challenge
- Scalability and manufacturing challenges: Producing nanotechnology-based drug carriers at a commercial scale presents significant challenges in maintaining consistency, stability, and quality. The manufacturing process requires specialized equipment, precise formulation techniques, and stringent quality control measures to ensure batch-to-batch reproducibility. Variations in nanoparticle size, surface properties, and drug encapsulation efficiency can impact therapeutic efficacy and safety. Overcoming these hurdles demands advanced production technologies, optimized protocols, and regulatory compliance, making large-scale commercialization complex and resource-intensive in the market.
- High market competition and intellectual property issues: The nanotechnology drug delivery market is highly competitive, with companies facing intense patent disputes and intellectual property challenges. To gain a competitive edge, firms must invest heavily in developing unique formulations and securing patents, which increases research and legal costs. Lengthy patent approval processes and litigation can delay commercialization, slowing market entry. Additionally, overlapping patents and regulatory complexities further complicate innovation, making it difficult for new entrants to establish themselves in this evolving industry.
Nanotechnology Drug Delivery Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
11.6% |
|
Base Year Market Size (2024) |
USD 97 billion |
|
Forecast Year Market Size (2037) |
USD 362 billion |
|
Regional Scope |
|
Nanotechnology Drug Delivery Segmentation
Technology (Nanoparticles, Nano suspensions, Liposomes, Micelles, Others)
By technology, the nanoparticles segment is poised to dominate nanotechnology drug delivery market share of around 39.7% by the end of 2037. The segment is growing due to its ability to enhance drug solubility, stability, and targeted delivery. They enable precise drug release at disease sites, improving therapeutic efficacy while minimizing side effects. Increasing demand for cancer treatments, neurological therapies, and chronic disease management fuels innovation in nanoparticle-based systems. Further, advancements in polymeric, lipid, and metal nanoparticles are driving adoption and are supported by rising R&D investments and regulatory approvals worldwide.
Application (Oncology and Hematology, Infectious Diseases, Orthopedics, Neurology, Urology, Immunology, Others)
By application, the oncology and hematology segment is poised to garner the majority of nanotechnology drug delivery market share over the forecast period. The segment’s growth is attributed to the rising global cancer burden and the need for targeted, less-toxic therapies. According to the WHO, the global cancer burden is rising, with 20 million new cases and 9.7 million deaths in 2022. By 2050, new cases are projected to reach 35 million, showcasing a 77% increase from 2022. Advances in liposomal, polymeric, and metallic nanoparticles enhance chemotherapy and immunotherapy effectiveness. As a result, the growing focus on nanomedicine is driving this segment’s expansion in oncology and hematology treatments.
Our in-depth analysis of the global market includes the following segments:
|
Technology |
|
|
Application |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportNanotechnology Drug Delivery Industry - Regional Synopsis
North America Market Statistics
North America nanotechnology drug delivery market is projected to dominate revenue share of over 43.5% by 2037, With at least one chronic illness affecting almost 45% of the total population in America (CDC), the demand for advanced drug delivery systems is rising. Additionally, the regions' shift toward personalized medicine boosts adoption in this sector, as nanocarriers enhance precision by tailoring release profiles and targeting specific cells. This improves therapeutic outcomes and minimizes adverse effects, fueling the growth of the nanotechnology drug delivery market.
The U.S. FDA’s streamlined regulatory pathways and faster approvals for nanomedicine are accelerating market adoption. Combined with significant funding from the government and private investors, such as NIH grants, these efforts support nanomedicine research, clinical trials, and mass commercialization. This regulatory and financial support fosters innovation in nanotechnology drug delivery, enabling faster development of advanced therapies, improving treatment efficacy, and expanding market opportunities. These factors collectively drive the growth of the U.S. nanotechnology drug delivery market.
The shift toward genomic therapy in Canada is driving the adoption of nanotechnology drug delivery. For instance, in March 2025, Genome Canada commenced the Canadian Precision Health Initiative (CPHI), backed by a USD 81 million in federal investment. This personalized approach improves treatment efficacy, signifying a prosperous future for nano-sized materials and delivery systems. Subsequently, the market for nanotechnology drug delivery systems in Canada continues to expand, driven by the increasing need for affordable and accessible precision medications.
APAC Market Analysis
The APAC nanotechnology drug delivery market is expected to garner the fastest CAGR over the forecast period. The expanding pharmaceutical and biotech sectors in China, India, and Japan are driving investments in nanotechnology-based drug delivery to enhance efficacy. Simultaneously, the shift toward personalized medicine is boosting demand for nanocarriers, which enable patient-specific drug formulations for long-term therapeutic action. This combination of industry growth and clinical advancements is accelerating the adoption of nanotechnology drug delivery, creating new industry opportunities and driving overall nanotechnology drug delivery market expansion in Asia Pacific.
The growing focus on precision medicine in China is driving demand for nanotechnology-based drug delivery. The emerging biotechnology and developing healthcare infrastructure across the nation are fueling innovation in this discipline. Simultaneously, ongoing discoveries in nanocarriers, such as liposomes, dendrimers, and polymeric nanoparticles, are improving drug solubility, stability, and controlled release. This combination of driving forces is propelling the growth of China’s market.
The well-established bioeconomy and expanding access to advanced therapies in India are broadening the application of the nanotechnology drug delivery market. India's healthcare access and quality index score notably improved in recent years, increasing from 44.8 (out of 100) in 2015 to 67.3 in 2020, as per the International Trade Organization. On the other hand, the bioeconomy of India is predicted to surpass USD 150 billion by 2025 and USD 300 billion by 2030, as per the 2022 India BioEconomy Report. This indicates a possibility of inflation in the need for advanced technologies, including nanoparticle-based solutions.
Companies Dominating the Nanotechnology Drug Delivery Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Celgene Corporation
- Johnson & Johnson
- Nanobiotix
- Nanocarrier Co. Ltd.
- Merck & Co. Inc.
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- SkyePharma PLC
- Starpharma Holdings Limited
- Teva Pharmaceutical Industries Ltd.
Market players are actively seeking to increase their market share through a variety of strategies, including investments, strategic partnerships, acquisitions, and mergers. This approach not only strengthens their position but also diversifies their offering pipelines. Additionally, businesses are significantly engaging their resources in the development of innovative products to attract more customers and large investors. They are also focused on maintaining competency with strategized pricing, enhancing their appeal in such an evolving marketplace. Some of these prominent nanotechnology drug delivery market players include:
In the News
- In June 2024, NANOBIOTIX initiated a virtual KOL (key opinion leader) event to establish a fruitful conclusion on the efficacy of its functionalized hafnium oxide (HfO2) nanoparticle, NBTXR3, in combination with immunotherapy. The evaluation process of this event revealed promising results in treating advanced head & neck cancer.
- In September 2023, Evonik expanded its parenteral drug delivery portfolio with the launch of three new PLA-PEG di-block copolymers and a new nanoparticle formulation service. The company aimed to conquer the field of controlled and sustained release drug products by using sonication technology.
Author Credits: Radhika Pawar
- Report ID: 7444
- Published Date: Apr 03, 2025
- Report Format: PDF, PPT
